Solid lipid nanoparticles mediate non-viral delivery of plasmid DNA to dendritic cells
Source abstract
Abstract
There is an increasing demand for novel DNA vaccine delivery systems, mainly for the non-viral type as they are considered relatively safe. Therefore, solid lipid nanoparticles (SLNs) were investigated for their suitability as a non-viral DNA vaccine delivery system. SLNs were synthesised by a modified solvent-emulsification method in order to study their potential to conjugate with plasmid DNA and deliver them in vitro to dendritic cells using eGFP as the reporter plasmid. The DNA–SLN complexes were characterised by electron microscopy, gel retardation assays and dynamic light scattering. The cytotoxicity assay data supported their biocompatibility and was used to estimate safe threshold concentration resulting in high transfection rate. The transfection efficiency of these complexes in a dendritic cell line was shown to increase significantly compared to plasmid alone, and was comparable to that mediated by lipofectamine. Transmission electron microscopy studies delineated the pathway of cellular uptake. Endosomal escape was observed supporting the mechanism of transfection.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · Immune Response and Inflammation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (26)
Show source-provided references
1. Abhishek Vartak SJS (2016) Recent advances in subunit vaccine carriers. vaccines 4(2). doi: 10.3390/vaccines402001210.3390/vaccines4020012 ↗
2. Ahmed A, Abdellatif H (2015) Transfersomal nanoparticles of keratolytic and antibacterial agents for enhanced transdermal delivery. J Nan Adv Mat 2016:19–23
3. Apaolaza PS, Delgado D, Pozo-Rodríguez AD, Gascón AR, Solinís MÁ (2014) A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases. Int J Pharm 465:413–426. doi: 10.1016/j.ijpharm.2014.02.03810.1016/j.ijpharm.2014.02.038 ↗
4. Baxter D (2007) Active and passive immunity, vaccine types, excipients and licensing. Occup Med 57:552-556 doi: 10.1093/occmed/kqm11010.1093/occmed/kqm110 ↗
5. Bondi ML, Azzolina A, Craparo EF, Lampiasi N, Capuano G, Giammona G, Cervello M (2007) Novel cationic solid-lipid nanoparticles as non-viral vectors for gene delivery. J Drug Target 15:295–301. doi: 10.1080/1061186070132469810.1080/10611860701324698 ↗
6. Calabrese EJ, Baldwin LA (1997) A quantitatively-based methodology for the evaluation of chemical hormesis. Human and Ecological Risk Assessment (HERA) 3:545–55410.1080/10807039709383710 ↗
7. Dal Pizzol C et al (2014) Influence of surfactant and lipid type on the physicochemical properties and biocompatibility of solid lipid nanoparticles. Int J Env Res Public Health 11:8581–8596. doi: 10.3390/ijerph11080858110.3390/ijerph110808581 ↗
8. Domingos RF et al (2009) Characterizing manufactured nanoparticles in the environment: multimethod determination of particle sizes. Environ Sci Technol 43:7277–7284. doi: 10.1021/es900249m10.1021/es900249m ↗
9. Foged C, Brodin B, Frokjaer S, Sundblad A (2005) Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm 298:315–322. doi: 10.1016/j.ijpharm.2005.03.03510.1016/j.ijpharm.2005.03.035 ↗
10. Hotze EM, Phenrat T, Lowry GV (2010) Nanoparticle aggregation: challenges to understanding transport and reactivity in the environment. JEnv Qual 39:1909–1924. doi: 10.2134/jeq2009.046210.2134/jeq2009.0462 ↗
11. Keles E, Song Y, Du D, Dong WJ, Lin Y (2016) Recent progress in nanomaterials for gene delivery applications. Biomater Sci 4:1291–1309. doi: 10.1039/c6bm00441e10.1039/c6bm00441e ↗
12. Khan KH (2013) DNA vaccines: roles against diseases. GERMS 3:26–35. doi: 10.11599/germs.2013.103410.11599/germs.2013.1034 ↗
13. Kim HR, Kim IK, Bae KH, Lee SH, Lee Y, Park TG (2008) Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol Pharmaceutics 5:622–631. doi: 10.1021/mp800023310.1021/mp8000233 ↗
14. Mochizuki S, Kanegae N, Nishina K, Kamikawa Y, Koiwai K, Masunaga H, Sakurai K (2013) The role of the helper lipid dioleoylphosphatidylethanolamine (DOPE) for DNA transfection cooperating with a cationic lipid bearing ethylenediamine. Biochim Biophys Acta Biomembr 1828:412–418. doi: 10.1016/j.bbamem.2012.10.01710.1016/j.bbamem.2012.10.017 ↗
15. Mukherjee S, Ray S, Thakur RS (2009) Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci 71:349–358. doi: 10.4103/0250-474X.5728210.4103/0250-474X.57282 ↗
16. Nascimento IP, Leite LCC (2012) Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Res 45:1102-1111 doi: 10.1590/S0100-879X201200750014210.1590/S0100-879X2012007500142 ↗
17. Paillusson F, Dahirel V, Jardat M, Victor J-M, Barbi M (2011) Effective interaction between charged nanoparticles and DNA. Phys Chem Chem Phys 13:12603–12613. doi: 10.1039/C1CP20324J10.1039/C1CP20324J ↗
18. Radhakrishnan R, Kulhari H, Pooja D, Gudem S, Bhargava S, Shukla R, Sistla R (2016) Encapsulation of biophenolic phytochemical EGCG within lipid nanoparticles enhances its stability and cytotoxicity against cancer. Chem Phys Lipids 198:51–60. doi: 10.1016/j.chemphyslip.2016.05.00610.1016/j.chemphyslip.2016.05.006 ↗
19. Rakesh Tiwle DKS (2014) A detail comprehensive review on vaccines Int J Res Dev Pharm Life Sci 3:887-895
20. Rivlin PK, Raymond PA (1987) Use of osmium tetroxide-potassium ferricyanide in reconstructing cells from serial ultrathin sections. J Neurosci Methods 20:23–33. doi: 10.1016/0165-0270(87)90036-710.1016/0165-0270(87)90036-7 ↗
21. Savonnière S, Zeghari N, Miccoli L, Muller S, Maugras M, Donner M (1996) Effects of lipid supplementation of culture media on cell growth, antibody production, membrane structure and dynamics in hybridomas. J Biotech 48:161–173. doi: 10.1016/0168-1656(96)01392-210.1016/0168-1656(96)01392-2 ↗
22. Sharp FA et al (2009) Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A 106:870–875. doi: 10.1073/pnas.080489710610.1073/pnas.0804897106 ↗
23. Spurr AR (1969) A low-viscosity epoxy resin embedding medium for electron microscopy. J Ultrastruct Res 26:31–4310.1016/S0022-5320(69)90033-1 ↗
24. Steinman RM (2007) Dendritic cells: versatile controllers of the immune system. Nat Med 13:1155–1159. doi: 10.1038/nm164310.1038/nm1643 ↗
25. Taki A, Smooker P (2015) Small wonders—the use of nanoparticles for delivering antigen. Vaccine 3:63810.3390/vaccines3030638 ↗
26. Yu W, Liu C, Liu Y, Zhang N, Xu W (2010) Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages. Pharm Res 27:1584–1596. doi: 10.1007/s11095-010-0149-z10.1007/s11095-010-0149-z ↗